Estimated read time: 2-3 minutes
This archived news story is available only for your personal, non-commercial use. Information in the story may be outdated or superseded by additional information. Reading or replaying the story in its archived form does not constitute a republication of the story.
NEW YORK (AP) — Stocks are solidly higher in early trading on Wall Street after the government reported an encouraging burst of hiring last month. Gap jumped after reporting strong sales for June. Drug developer Juno Therapeutics sank after halting a study on a potential leukemia treatment.
WASHINGTON (AP) — The Labor Department says employers shook off two months of weak hiring and added 287,000 jobs in June. The hiring spurt marks a sharp improvement from May's dismal showing, when just 11,000 jobs were added. A modest 144,000 jobs were created in April. May's figure was revised lower, while April's is higher than initially reported. The unemployment rate rose to 4.9 percent from 4.7 percent as more Americans began looking for jobs.
WASHINGTON (AP) — The International Monetary Fund says Britain's decision to leave the European Union will trim economic growth this year and next across the 19 countries that share the euro currency. The global lending agency expects the eurozone economy to grow 1.6 percent this year and 1.4 percent in 2017. Before the so-called Brexit vote, the IMF was projecting 1.7 percent growth this year and next. The eurozone grew 1.7 percent last year, fastest since 2010.
NEW YORK (AP) — Shares of Juno Therapeutics are plunging after the biotechnology company halted a mid-stage study on a potential leukemia treatment following two patient deaths. Juno shares were down 27 percent in morning trading. The company says it put the study on hold after it added the chemotherapy drug fludarabine (floo-DAYR'-uh-been) to the regimen. It has proposed continuing the study without fludarbine.
NEW YORK (AP) — Consumer Reports says a Samsung phone that's advertised as being "water resistant" actually isn't. The problem appears limited to the Galaxy S7 Active, a rugged model available only through AT&T in the U.S. The standard S7 and S7 Edge models have the same claims on water resistance and passed tests. Consumer Reports says it can't recommend the Active because it doesn't meet Samsung's own claims.
Copyright © The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.








